Pharmafile Logo

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

March 18, 2024 |  

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

- PMLiVE

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.

Why in-person-only should be a thing of the past

I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:

  • Expensive
  • Associated with a large environmental footprint
  • Inflexible and not accommodating to everyone’s schedules, work or personal commitments, and preferences
  • Susceptible to last-minute no-shows due to flight delays or poor driving conditions

Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:

  • Valuable time wasted on didactic data presentations
  • Very limited “air time” per participant
  • Uneven share of voice, with more extroverted or senior advisors tending to take up more speaking time
  • A tendency for answers to be “knee-jerk reactions” rather than thought-through responses and for people to simply ‘agree’ with others
  • Limited ability to dive deeper into interesting or controversial ideas
  • Suboptimal diversity of advisors due to potential geographic or language barriers

Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…

[Read the full article here]

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Navigating the Nuances of Europe’s MedTech Industry

Richard Houlihan, CEO of EirMed, explores topics related to EUDAMED, the European Databank for Medical Devices, including the key pain points and concerns MedTech companies encounter related to EUDAMED and...

Pharma, Technology, and Healthcare in the New Normal

Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma conducts clinical trials and interacts with...

Traversing the Medtech Regulatory Landscape in the Interest of Patients

Dr. Bassil Akra, CEO of AKRA TEAM GmbH, takes a deep dive into the new approval process for medical devices in the EU and shares how his company is supporting...

Scanning for Health Indicators and Risks Through Your Smartphone

Vlado Bosanac, Co-Founder & Head of Strategy and Revenue Growth at Advanced Human Imaging, dives into the implications of increased integration of tech and data into daily life for the...

Virtual MSL/Sales training programs and events

Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events

Top 10 Benefits of Virtual Advisory Boards

As the world is slowly starting to open up again, it can be tempting to rush back to the pre-pandemic days of in-person advisory boards. However, it would be foolish...

Amplifying Opinions of Patients & Caregivers for Higher Quality of Care

Pam Cusick, Senior Vice President of Rare Patient Voice, dives into diversity, equity, and inclusion in Pharma and clinical trials; ways to enhance the patient’s voice in their treatment journey...

The Future of MedTech: Streamlined Clinical Data Collection & Management

Jón Ingi Bergsteinsson, Co-founder & CCO at SMART-TRIAL, explores the barriers to, and benefits of, digitalization of clinical operations and trials in the MedTech industry, plus much more!

Digital Opinion Leaders (DOLs): Who are they and how can Pharma engage them?

With our growing dependence on social media, Digital Opinion Leaders are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. But who are these DOLs, and...